Equillium, Inc. (NASDAQ: EQ) filed a Form 4 disclosing insider transactions by Christine Zedelmayer, the company’s Senior Vice President and Chief Operating Officer. On February 19, 2026, Zedelmayer sold 109,375 shares and 76,562 shares of the company’s common stock. The sale prices ranged from $1.7406 to $1.7814 per share, producing a combined transaction value of $328,104.
In the same trading session, Zedelmayer exercised stock options to acquire the identical quantities of shares: 109,375 shares at an exercise price of $0.785 and 76,562 shares at $0.73. The total cost to acquire those shares through option exercise was $141,749.
The Form 4 filing specifies that the sale was effected pursuant to a Rule 10b5-1 trading plan that Zedelmayer adopted on August 27, 2025. The 10b5-1 arrangement is noted in the filing as the mechanism by which the reported sale was executed.
Market data cited in the filing notes that Equillium’s stock has shown pronounced recent gains, with a 13% increase over the past week and a 165% return over the last year. That performance is attributed to InvestingPro data, which is referenced as offering 12 additional ProTips for EQ investors.
Separately, the company has attracted analyst attention. Stifel has initiated coverage on Equillium with a buy rating and set a $5.00 price target. Stifel’s rationale centers on Equillium’s work on a novel treatment for inflammatory bowel disease, highlighting the company’s EQ504 candidate. While EQ504 is described as preclinical, Stifel pointed to the market need for new IBD therapies and the potential for such candidates to expand treatment options either as standalone therapies or in combination with other modalities.
These filings and analyst coverage underline recent activity around Equillium within the pharmaceutical and small-cap stock spheres. The simultaneous option exercises and sale, the use of a 10b5-1 plan, the cited stock momentum, and the fresh analyst initiation are the principal developments detailed in the company disclosures and analyst note.
Key points
- Insider sale: Christine Zedelmayer sold 185,937 shares on February 19, 2026, for $328,104 at prices between $1.7406 and $1.7814.
- Option exercise: Zedelmayer exercised options to acquire 185,937 shares at $0.785 and $0.73, for a total exercise cost of $141,749.
- Analyst coverage: Stifel initiated coverage with a buy rating and a $5.00 price target, citing potential for the preclinical EQ504 IBD candidate.
Risks and uncertainties
- EQ504 remains preclinical, indicating development and regulatory uncertainty for the candidate.
- Equillium operates in the competitive IBD therapeutic market where new treatments are needed but clinical outcomes are uncertain.
- The stock has shown rapid recent gains (13% over a week; 165% over a year), which may reflect elevated market volatility.